Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• IL4 and IL13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases

  80% confidence

• The approval of Dupixent for certain adults and adolescents with chronic spontaneous urticaria in the European Union represents the first innovation for patients with this disease in over a decade. Physicians now have a new approach for CSU with Dupixent, as the only treatment that inhibits IL4 and IL13. This approval further demonstrates the ability of Dupixent to advance the treatment landscape for yet another chronic type 2 inflammatory disease.

  80% confidence

• The unpredictable nature of chronic spontaneous urticaria leaves patients guessing when they'll have their next outbreak of disruptive, debilitating hives and itch, which can make life challenging. Dupixent is proven to reduce these intense symptoms and has the potential to make a positive impact on people struggling to control this disease.

  80% confidence

• Standard-of-care, first-line treatment options like antihistamines offer limited relief for many people living with uncontrolled chronic spontaneous urticaria. Dupixent significantly reduced symptoms of CSU and led to more patients experiencing well-controlled disease or a complete response compared to placebo in two phase 3 studies.

  80% confidence